{{Refimprove|date =January 2017}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477869670
| IUPAC_name = (2''R'')-&#x200b;1-&#x200b;{4-&#x200b;[(1a''R'',10b''S'')-&#x200b;1,1-&#x200b;difluoro-&#x200b;1,1a,6,10b-&#x200b;tetrahydrodibenzo&#x200b;[''a'',''e'']&#x200b;cyclopropa&#x200b;[''c'']&#x200b;[7]&#x200b;annulen-&#x200b;6-&#x200b;yl}-&#x200b;3-&#x200b;(quinolin-&#x200b;5-&#x200b;yloxy)&#x200b;propan-&#x200b;2-&#x200b;ol
| image = Zosuquidar.svg
| width = 250px

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 167354-41-8
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 153997
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 24599682
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = AB5K82X98Y
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06387
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 444172

<!--Chemical data-->
| C=32 | H=31 | F=2 | N=3 | O=2 
| molecular_weight = 527.61 g/mol
| smiles = Cl.Cl.Cl.FC4(F)[C@@H]3c1ccccc1C(c2c(cccc2)[C@@H]34)N5CCN(CC5)C[C@@H](O)COc7c6cccnc6ccc7
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C32H31F2N3O2/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27/h1-14,21,29-31,38H,15-20H2/t21-,29-,30+,31-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IHOVFYSQUDPMCN-DBEBIPAYSA-N
}}

'''Zosuquidar''' (also LY-335979) is an experimental [[antineoplastic]] [[drug]]. In 2010, it was announced that a phase III trial for the treatment of [[acute myeloid leukemia]] (AML) and [[myelodysplastic syndrome]] did not meet its primary endpoint<ref>http://www.clinicaltrials.gov/show/NCT00046930</ref> and Eli Lilly discontinued its development.

Zosquidir [[Enzyme inhibition|inhibits]] [[P-glycoprotein]]s. Other drugs with this mechanism include [[tariquidar]] and [[laniquidar]]. P-glycoproteins are trans-membrane [[protein]]s that pump foreign substances out of cells in an [[Adenosine triphosphate|ATP]] dependent fashion. Cancers overexpressing P-glycoproteins are able to pump out therapeutic molecules before they are able to reach their target, effectively making the cancer multi-drug resistant. Zosuquidar inhibits P-glycoproteins, inhibiting the efflux pump and restoring sensitivity to chemotherapeutic agents.

Zosuqidar was initially characterized by Syntex Corporation, which was acquired by [[Hoffmann-La Roche|Roche]] in 1990. Roche licensed the drug to [[Eli Lilly]] in 1997. It was granted [[orphan drug status]] by the FDA in 2006 for AML.

==References==
<references/>

[[Category:Experimental cancer drugs]]
[[Category:Organofluorides]]
[[Category:Cyclopropanes]]
[[Category:Quinolines]]
[[Category:Piperazines]]
[[Category:Tetracyclic compounds]]